UNREAL: Ground-Breaking Cancer Treatment Snubbed By Government For This SICK REASON


A story by the state-funded British Broadcasting Company refused to mention that a pioneering cancer treatment was made in Israel, even though the treatment got extensive coverage from the BBC.

The treatment combines the drugs ipilimumab and nivolumab to combat advanced, aggressive melanoma. That would have been an almost certain death sentence just years ago, with the average patient surviving only nine months.

However, 69 percent of people who received the combination of drugs experienced tumor shrinkage, and fully one-fifth of patients were ostensibly cancer-free.

Breitbart reported that Dr. Yaakov Schachter, head of the Ella Institute at Sheba Medical Center in Tel HaShomer, Israel, developed the drug combination.

However, in a 600-word article in which the BBC said the approval of the drug combination “is one of the fastest in NHS history and is likely to be adopted throughout the U.K.,” they couldn’t even mention where it was developed or who developed it.

They did have time to include a quote from Prof. Carole Longson from the National Institute for Health and Care Excellence, who said, “These promising new immunotherapy treatments for advanced melanoma look set to significantly extend the life of people with the condition.”

Israel is one of the most advanced democracies on earth. In spite of the fact that it has been assailed from every corner of the Muslim world, it has managed to thrive, particularly in the areas of high technology and pharmaceuticals.

The left wants to denounce Israel’s strident defense of its democracy and Jewish homeland, but they also want to benefit from the fruits that this arrangement and set of values produce.

If the BBC and the U.K. really want to snub Israel, here’s what you do: Don’t buy the cancer drug. That oughta teach ’em.

Ah, yes, but people want to live. That’s why it’s time to acknowledge the Israelis and their contributions to our life here on earth. Please like and share on Facebook and Twitter if you agree.


Leave a Reply

Your email address will not be published. Required fields are marked *